ArticleFrontiers in immunology2025
Multidimensional transcriptomics based to illuminate the mechanisms of taurine metabolism in immune resistance of pancreatic cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Unveiling the role of spatial transcriptomics in the analysis of the tumor immune microenvironment (Review).International journal of molecular medicine · 2026Review
- Organ-Specific Migration License (OSML) theory: a novel paradigm for spatiotemporal regulation and intervention of cross-organ immune cell migration in tumor immune responses.Cell communication and signaling : CCS · 2026Review
- Bioinformatics analysis of TCGA data identifies a taurine metabolism-related subtype classification for predicting prognosis in colon adenocarcinoma.Journal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer, a highly malignant tumor of the digestive system, is characterized by a tumor microenvironment with a high degree of immunosuppression. This immunosuppressive property poses significant challenges, as it hampers the effective infiltration of immune cells and impairs their ability to exert cytotoxic effects. The metabolic process of taurine has emerged as a crucial factor in modulating the functions and activities of immune cells. Intervening in taurine metabolism holds the potential to reshape the tumor immune microenvironment, thereby enhancing the ability of immune cells to recognize and eliminate tumor cells. To explore the potential therapeutic relationship between taurine metabolism disorders and pancreatic cancer immunotherapy, we employed multiple software packages, including "Seurat", "DoubletFinder", "Harmony", "GSVA", and "CellChat" to analyze single-cell data and spatial transcriptomic data of pancreatic cancer. In the present study, four distinct tumor cell subsets, namely RPS4Y1+ tumor cells, LYZ+ tumor cells, CPE+ tumor cells, and MKI67+ tumor cells, were identified for the first time. The CNV score and taurine metabolism score highlighted the significant role of RPS4Y1+ tumor cells within the immunosuppressive microenvironment of pancreatic cancer. Through cell-communication analysis, the crosstalk among fibroblasts, CD8+ T cells, and RPS4Y1+ tumor cells was identified, offering novel insights into immunotherapy strategies, which was strengthened by the co-localization analysis of spatial transcriptomics. Furthermore, by conducting a combined analysis of survival data, we identified LY6D as a potential therapeutic target. Through co-culture experiments with fibroblasts, we uncovered the underlying mechanism of LY6D in regulating taurine metabolism imbalance within the immunosuppressive microenvironment of pancreatic cancer. The establishment of the "taurine-immune crosstalk" criteria in this study effectively paves the way for pancreatic cancer immunotherapy. In conclusion, the current research underscores the significance of taurine metabolism in the immunosuppressive microenvironment of pancreatic cancer. Targeting taurine metabolism may represent a crucial approach for reversing the "stiff-cancer" characteristics of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.